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The cardiovascular disease myocarditis is characterized by inflammation and necrosis of cardiac muscle.
This disease has been associated with various viral etiologies, including cytomegalovirus (CMV). Murine CMV
(MCMV) infection of adult BALB/c mice produces a disease with acute and chronic phases similar to that
found in humans. In our murine model, we have investigated the therapeutic efficacy of antiviral drug
administration on myocarditis. Two drugs commonly used for CMV treatment, ganciclovir and cidofovir, were
subjected to trials, with both drugs showing potent antiviral activity against MCMV both in vitro and in vivo.
The acute phase of myocarditis was significantly reduced when antiviral therapy commenced 24 h postinfection.
Such treatment also reduced the severity of the chronic phase of myocarditis. In contrast, antiviral treatment
commencing after the acute phase had no effect on chronic myocarditis. Reinfection of mice with MCMV
caused exacerbation of myocardial inflammation. Such an increase in severity of myocarditis could be pre-
vented with either ganciclovir or cidofovir treatment, but the preexisting inflammation and necrosis of the
myocardium persisted. These data highlight possible therapeutic uses of antiviral drugs in viral myocarditis
as well as further elucidating the pathogenic nature of the disease.
The cardiovascular disease myocarditis is characterized by
inflammation and necrosis of cardiac muscle. The disease
ranges from transient inflammation to a fulminant syndrome
with manifestations that may include heart failure, arrhyth-
mias, and sudden death. Acute and chronic myocarditis can be
induced by a number of agents, including viruses (31). Al-
though enterovirus infections are recognized as a leading cause
of myocarditis (27), evidence is accumulating that cytomega-
lovirus (CMV) is also of importance in inducing myocarditis in
humans (8, 11, 21).
The strict host specificity of CMV has not allowed the de-
velopment of a direct animal model for infection with human
CMV. However, murine CMV (MCMV) infection of mice
provides an excellent experimental model for investigation of
the development of disease. Previous work has shown that
MCMV infection of BALB/c mice induces myocarditis (17). A
mixed cellular infiltrate composed of polymorphonuclear neu-
trophils, macrophages, and mononuclear lymphocytes is ob-
served at 3 to 5 days, reaching a peak at 7 to 11 days after
MCMV infection. The chronic, autoimmune phase of myocar-
ditis is characterized by a predominantly mononuclear cellular
infiltrate, which gradually increases in severity and is main-
tained for at least 100 days postinfection.
A number of pathogenic mechanisms have been suggested
to account for the inflammation and necrosis found in this
disease. Early insult to cardiac tissue may involve direct viral
infection of the heart. Alternatively, the production of an an-
tiviral immune response during viral infection may cause ne-
crosis of infected myocytes through the release of inflamma-
tory mediators (23, 25, 30, 32). Furthermore, an antiviral
immune response that cross-reacts with self antigens, such as
myosin, may lead to myocyte necrosis and autoimmune disease
(9, 11, 12, 15, 18, 34). However, despite considerable advances
in medicine and a greater understanding of myocarditis, treat-
ment for this disease remains primarily supportive. The ther-
apy regime is focused on the myocardial dysfunction and in-
cludes such measures as oxygenation and the administration of
inotropic agents to increase cardiac output.
The role of virus as a trigger for myocarditis is very clear;
therefore, the therapeutic effects of antiviral drugs on the sub-
sequent course of myocarditis has been the focus of recent
research. Studies of the coxsackievirus B3 (CB3) myocarditis
mouse model have demonstrated a biphasal pattern of disease
(26) and have shown some promise for antiviral drugs, with
ribavirin being subjected to trials as a possible therapeutic
agent (13). Early administration of ribavirin resulted in inhi-
bition of viral replication, a reduction in myocardial damage
during the acute phase of disease, and increased survival. How-
ever, when treatment commenced on day 4 of the infection,
myocardial damage was reduced but there was no survival
benefit. Our previous research has shown that MCMV infec-
tion of susceptible mice clearly causes the onset of myocarditis
(17). We have therefore examined the therapeutic efficacies of
several antiviral agents in our MCMV myocarditis model.
In the present study, we have examined the therapeutic
effects of two antiviral drugs, ganciclovir (GCV) and cidofovir
(CDV). GCV (9-[1,3-dihydroxy-2-propoxymethyl]guanine) has
been used extensively in the treatment of CMV retinitis in
immunocompromised patients, especially those with AIDS (4).
CMV possesses a unique viral kinase capable of phosphorylat-
ing GCV to GCV monophosphate in infected cells (20). GCV
monophosphate is readily converted by cellular enzymes to
GCV triphosphate (33), which is the active form of the drug
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and inhibits viral DNA polymerase (7). CDV, 1-[(S)-3-hy-
droxy-2-(phosphonomethoxy)propyl] cytosine dihydrate, is a
monophosphate nucleotide analogue and undergoes cellular
phosphorylation to an active diphosphate form (10). CDV
competitively inhibits the incorporation of deoxycytosine-59-
triphosphate by viral DNA polymerase into viral DNA (36).
Once incorporated into viral DNA, it slows further DNA syn-
thesis and causes DNA destabilization. While the antiviral
potency of these drugs is unquestionable, their therapeutic
value for CMV-induced myocarditis is unknown. In this study,
we have used our well-established MCMV myocarditis mouse
model to examine the efficacies of GCV and CDV. We have
examined various treatment regimes, focusing on the effect
that these drugs have on the acute and chronic phases of
myocarditis. Our results provide valuable insights into the ef-
ficacy of antiviral treatments for virus-induced myocarditis as
well as further elucidating the pathogenesis of the disease.
MATERIALS AND METHODS
Mice. Specific-pathogen-free inbred male BALB/c mice (6 to 8 weeks old;
seronegative for MCMV) were obtained from the Animal Resources Centre
(Perth, Western Australia) and maintained under minimal disease conditions.
Virus. Virulent MCMV (K181 strain [Perth]) was prepared by salivary gland
passage in mice and stored in the gas phase of liquid nitrogen (16). The virus was
originally obtained from D. Lang (Duke University, Durham, N.C.) and after
serial passages was designated the K181 MCMV (Perth) strain. The virulent wild
isolate of MCMV designated G4 was originally isolated by T. Scalzo (University
of Western Australia) from wild mice trapped in Geraldton, Western Australia,
and was similarly prepared as a salivary gland virus stock. Quantification of
infectious MCMV was determined by plaque assay using mouse embryo fibro-
blast (MEF) monolayers, as previously described (16). Virus titers are expressed
as the mean PFU per gram of tissue 6 standard deviation (SD), and the limit of
detection was 100 PFU/g.
Drugs. GCV (Roche Products, Sydney, Australia) and CDV (Pharmacia &
UpJohn, Sydney, Australia) were used in our MCMV model. These antiviral
drugs dissolved in pyrogen-free saline were given to mice via the intraperitoneal
(i.p.) route.
Plaque reduction assay. The sensitivities of the K181 laboratory strain and the
G4 wild isolate of MCMV to antiviral drugs were assessed by plaque reduction
assay using MEF monolayers (19). The infected cells were overlaid with a
medium containing 1% methylcellulose and various concentrations of an antivi-
ral drug and were further incubated for 3 days. The 50% inhibitory concentration
corresponds to the drug dose achieving 50% plaque reduction.
Primary MCMV infection. Mice were infected by the i.p. route with 104 PFU
of MCMV diluted in pyrogen-free saline. In studies examining the acute phase
of myocarditis, mice were infected with MCMV on day 0. Drug treatments of
various doses commenced on day 1 postinfection (p.i.) and continued daily.
Saline was similarly administered as a placebo. Hearts, livers, spleens, and sali-
vary glands were removed from groups of five mice on day 7 p.i. The hearts were
transected along the midline and processed with Bouin’s fixative for histological
examination. The spleens, livers, and salivary glands were homogenized, and
infectious virus was quantified by plaque assay. In experiments examining the
chronic phase of myocarditis, mice were infected on day 0 and treatment com-
menced on day 1 p.i. The mice received either 40 mg of GCV per kg of body
weight per day or 5 mg of CDV/kg/day (effective doses were determined from
earlier experiments with acute virus infection). Treatment continued until day
7 p.i. The hearts were removed on day 35 p.i. and processed for histology. In a
separate experiment, mice were infected on day 0 and treatment, with either 40
mg of GCV/kg/day or 5 mg of CDV/kg/day, commenced on day 14 p.i. and
continued until day 35 p.i., when the hearts were removed for histology. Control
mice were either uninfected and drug treated or MCMV infected without drug
treatment.
Secondary MCMV infection. In experiments examining the treatment of myo-
carditis upon virus reinfection, mice were infected with K181 MCMV on day 0
and then reinfected with either K181 or G4 MCMV on day 56 p.i. Treatment
with either 40 mg of GCV/kg/day or 5 mg of CDV/kg/day commenced on day 57
post-initial infection. Hearts, livers, spleens, and salivary glands were removed
from groups of five mice on day 63 post-initial infection (i.e., day 7 postreinfec-
tion). The hearts were processed for histology, and the spleens, livers, and
salivary glands were homogenized for determination of virus titer by plaque
assay. Control mouse groups were either K181 MCMV infected with no rein-
fection, K181 MCMV infected with K181 MCMV reinfection, or K181 MCMV
infected with G4 MCMV reinfection.
Heart histopathology. Myocarditis was scored from hematoxylin- and eosin-
stained heart sections as the average number of foci of cellular infiltration 6 SD
from five mice per group, as previously described (6).
Statistical analysis. The Student t test was used to assess differences between
groups of data. P values of 0.05 or less were considered to be statistically
significant.
RESULTS
In vitro antiviral activities of GCV and CDV for MCMV.
The antiviral activities of GCV and CDV were determined by
plaque reduction assays. The K181 laboratory strain and the
G4 wild isolate of MCMV were inhibited with GCV concen-
trations of 8.9 and 5.6 mM, respectively, for 50% reduction in
plaques formed in virus-infected MEF monolayers (data not
shown). The 50% inhibitory concentrations for CDV were 0.17
and 0.23 mM, respectively, against K181 and G4 viruses. These
values are similar to previously reported values for GCV and
CDV (24) and confirm that these antiviral drugs are effective
against our laboratory strain and the wild isolate of MCMV.
Antiviral treatment of acute MCMV infection and myocar-
ditis in mice. The antiviral effect of GCV and CDV on virus
replication in the major target organs, liver, spleen, and sali-
vary gland, and the therapeutic effect of such antiviral agents
on the acute phase of MCMV-induced myocarditis were inves-
tigated. Adult BALB/c mice were infected with K181 MCMV
and then treated with various doses of GCV or CDV com-
mencing day 1 p.i. MCMV-infected mice treated with GCV
showed significant (P , 0.05) reductions in virus titers in the
spleen and salivary gland with all doses of this drug compared
to untreated MCMV-infected mice (Fig. 1A). MCMV-infected
mice treated with CDV showed a significant (P , 0.05) reduc-
tion in virus titers in the salivary gland with all doses compared
to the untreated MCMV-infected mice (Fig. 1B). While the
reductions in the spleen and liver were not statistically signif-
icant, doses of 5 and 10 mg of CDV/kg/day reduced viral titers
in these organs to the limit of detection of the plaque assay
(Fig. 1B).
Myocarditis was significantly reduced (6.2-fold reduction;
P , 0.05) on day 7 in MCMV-infected mice treated with either
25 or 40 mg of GCV/kg/day (Fig. 2A). However, 12 mg/kg/day
had no observed effect on the severity of myocarditis compared
to that in the untreated MCMV-infected mice. CDV-treated
mice showed significant reduction (36-fold reduction; P ,
0.05) in myocarditis on day 7 for all doses of CDV, with no
detectable inflammation observed in mice given doses of 5 and
10 mg/kg/day (Fig. 2B). As expected, myocarditis was unde-
tectable in control uninfected BALB/c mice treated with the
above-mentioned defined doses of either GCV or CDV (data
not shown).
Antiviral treatment of chronic MCMV-induced myocarditis.
The efficacy of antiviral treatment on the chronic phase of
MCMV-induced myocarditis was next examined. A significant
reduction in chronic myocarditis was observed under both the
GCV and CDV treatment regimes (1.8- and 2.8-fold reduction,
respectively; P , 0.05) (Fig. 3); however, the disease was not
completely abolished.
In a separate experiment, antiviral treatment commenced
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after myocarditis was established, with no decrease in myocar-
ditis observed on day 35 with either the GCV or CDV treat-
ment regime (Fig. 4).
Antiviral treatment of MCMV reinfection. The effect of
GCV and CDV was examined in mice reinfected with either
the same or a different strain of MCMV during the chronic
phase of myocarditis. On day 7 postreinfection, livers, spleens,
and salivary glands were removed for virus quantitation, and
hearts were examined histologically for myocarditis. Reinfec-
tion of mice with K181 significantly exacerbated myocarditis
(1.3-fold increase). An increase in cardiac inflammation was
also observed after reinfection of mice with G4 MCMV (1.2-
fold increase); however, this was not statistically significant
(Fig. 5). Treatment with GCV or CDV resulted in a slight
decrease in myocarditis in unreinfected mice, but both drugs
caused a significant decrease in disease in both the K181 and
G4 MCMV-reinfected animals (2.2- and 2.6-fold reduction,
respectively; P , 0.05) (Fig. 5). As expected, no virus was
detected by plaque assay in any of the target organs taken from
previously infected mice challenged with either MCMV strain
(data not shown).
DISCUSSION
This study examined the potential use of the antiviral drugs
GCV and CDV as therapeutic agents in a CMV-induced myo-
carditis model using adult BALB/c mice. Antiviral therapy was
tried, as the role of MCMV in the induction of cardiac inflam-
mation is unquestionable. Our results clearly support this viral
role, but additional mechanisms also contribute to the devel-
opment of myocarditis. We have shown that early treatment
(day 1 p.i.) with either GCV or CDV significantly reduces
myocarditis in the acute phase of disease (day 7 p.i.). This
finding supports the hypothesis that early myocardial inflam-
mation is mediated either directly or indirectly by virus infec-
tion. Data from the CB3 model of myocarditis shows that the
virus alone can cause direct myocyte death without involving
any immune mechanism of host defense (9, 22). During the
early stage of CB3 disease, virus can be readily obtained from
the heart tissue (12), and in situ hybridization studies using
CB3-infected mice demonstrated that viral infection leading
directly to myocyte necrosis and inflammatory foci were con-
sistently associated with virus-infected cells (9, 12, 14). In our
MCMV model of myocarditis, virus titers in the heart are
extremely low—indeed, 100-fold lower than CB3 titers in the
FIG. 1. Antiviral therapy reduces MCMV titers in major target
organs. BALB/c mice were inoculated with 104 PFU of MCMV i.p. at
day 0 and treated with GCV (A) or CDV (B) daily from day 1 to 7 p.i.
or treated with saline as a placebo. The average numbers (1SD) of
PFU per gram of liver, spleen, and salivary gland at day 7 p.i. from
groups of five mice per dose are shown.
FIG. 2. Early antiviral treatment reduces the severity of acute
MCMV-induced myocarditis. BALB/c mice were inoculated with 104
PFU of MCMV i.p. at day 0 and treated with either GCV (A) or CDV
(B) daily from day 1 to 7 p.i. or treated with saline as a placebo. The
average numbers (1SD) of inflammatory foci per heart section at day
7 p.i. from groups of five mice per dose are shown.
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heart (6, 28, 30). Although treatment with 12 mg of GCV/kg/
day significantly reduced MCMV titers in the spleen, liver, and
salivary gland, this dose of GCV had no effect on myocarditis
severity. However, higher doses of the drug further reduced
viral titers and caused significant decreases in myocardial in-
flammation. This indicates that MCMV-induced myocarditis
cannot be treated in a dose-dependent manner with antiviral
drugs; rather, viral titers must be reduced to a relatively low
level before any therapeutic effect can be observed in the acute
phase. Acute viral burdens in the liver have also been shown to
be decreased with GCV treatment of weanling BALB/c mice
infected i.p. with MCMV (2).
In the present study, we report that chronic MCMV-induced
myocarditis cannot be prevented by early antiviral treatment
with either GCV or CDV given during the acute stage of
infection. While the severity of chronic myocarditis was re-
duced, inflammation and necrosis were still observed. During
the chronic phase of disease, infectious MCMV cannot be
detected in the heart, spleen, liver, or salivary gland of suscep-
tible mice, providing supporting evidence that this phase is not
mediated by direct viral damage. We have also found that
treatment of mice with foscarnet (500 mg/kg/day), using a
regime similar to that for GCV and CDV, reduced virus titers
in the spleen and liver but was not effective at reducing acute
myocarditis (data not shown). However, this observation may
reflect the inadequacy of systemic delivery of foscarnet in our
animal model, since this drug is often administered to patients
as an infusion. Furthermore, antiviral treatment with either
GCV or CDV after the acute phase of disease and extending
into the chronic phase had no significant therapeutic effect.
This finding supports an important role for other governing
factors besides virus in the development of myocarditis follow-
ing virus infection.
We also found that susceptible mice reinfected with the
same or a different strain of MCMV during the chronic phase
of disease showed a significant increase in myocarditis. While
a previous CMV infection allowed rapid clearance of virus
upon reinfection, with no infectious virus detected on day 7
postreinfection, it did not protect against the development of
myocarditis. Antiviral treatment with GCV or CDV reduced
myocarditis severity in reinfected mice; however, inflammation
and necrosis indicative of the chronic phase were still evident.
FIG. 3. Early antiviral therapy reduces the severity of chronic
MCMV-induced myocarditis. BALB/c mice were inoculated with 104
PFU of MCMV i.p. on day 0 and treated with either GCV at 40
mg/kg/day (A) or CDV at 5 mg/kg/day (B) from day 1 to 7 p.i. or
treated with saline as a placebo. The average numbers (1SD) of
inflammatory foci per heart section on day 35 p.i. from groups of five
mice are shown.
FIG. 4. Late antiviral therapy has no therapeutic effect on chronic
MCMV-induced myocarditis. BALB/c mice were inoculated with 104
PFU of MCMV i.p. on day 0 and treated with either GCV at 40
mg/kg/day (A) or CDV at 5 mg/kg/day (B) from day 14 to 35 p.i. or
treated with saline as a placebo. The average numbers (1SD) of
inflammatory foci per heart section on day 35 p.i. from groups of five
mice are shown.
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Clearly, further myocardial damage is being caused by subse-
quent viral infections, with such reinfections able to be treated
with antiviral drugs. However, such treatment is not effective
for the existing chronic inflammation and necrosis, which is
possibly autoimmune in nature, induced by the primary CMV
infection.
Clinical trials of CDV for CMV retinitis in AIDS patients
have demonstrated efficacy in slowing the progression of this
disease and provided insights into toxicity, an adverse side
effect of this antiviral drug (28). However, emergence of drug-
resistant CMV mutants has been observed for CDV- and
GCV-treated AIDS patients (5). The molecular basis of such
de novo resistance is often described as mutations in the UL54
DNA polymerase gene (3, 29, 35). Combinatorial therapy us-
ing such antiviral agents, not necessarily administered simul-
taneously, may have desirable synergistic effects in vivo without
potential problems associated with the development of drug
resistance. Furthermore, incorporation of new analogues of
such antiviral compounds in therapeutic regimes may enhance
the potency of these agents at affecting early virus replication
(1).
Our results show that antiviral therapy is an effective treat-
ment for MCMV-induced myocarditis when initiated very
early in infection. Such early treatment provides protection
against severe acute myocarditis and reduces the level of
chronic myocarditis. However, our studies of treatment during
the chronic phase of disease showed no therapeutic effect in
the murine model, providing further evidence that an immu-
nopathogenic mechanism perpetuates the late phase of dis-
ease. Nonetheless, antiviral therapy is a viable option to pre-
vent exacerbation of disease when reinfection is recognized as
a high risk factor, especially in transplant patient groups. Our
study has highlighted possible clinical applications of antiviral
drugs as therapeutic agents in CMV-induced myocarditis as
well as providing further insights into the pathogenesis of this
disease.
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